SoftBank Leads $525 Million Fund Raise for U.K. Pharma Startup
- Oxford-based firm uses AI to help discover new pharmaceuticals
- New backers also include Mubadala, Farallon, and GT Healthcare
Photographer: Dhiraj Singh/Bloomberg
This article is for subscribers only.
Oxford-based Exscientia, a pharmaceutical company that uses artificial intelligence to discover new drugs, has raised a new round of funding worth as much as $525 million to expand its pipeline of drugs and technological capabilities.
The investment was led by SoftBank Group Corp.’s Vision Fund 2, with participation from previous investors Novo Holdings and BlackRock. Mubadala Investment Co., Farallon, Casdin, and GT Healthcare were among other new investors, the company said in a statement Tuesday.